Arcus Biosciences (RCUS) Debt Ratio (2024 - 2026)

Arcus Biosciences' (RCUS) quarterly Debt Ratio came in at 0.1 in Q1 2026, up 150.75% year-on-year from 0.04 in Q1 2025, and up 15.4% quarter-over-quarter from 0.09 in Q4 2025.

Arcus Biosciences (RCUS) Debt Ratio (2024 - 2026) Analysis & Trends

Arcus Biosciences' Debt Ratio history runs 3 years deep, the most recent figure standing at 0.1 for Q1 2026.

  • On a quarterly basis, Debt Ratio rose 150.75% year-over-year to 0.1 in Q1 2026; TTM through Mar 2026 was 0.1, a 150.75% increase from a year earlier, with the FY2025 full-year figure at 0.09, up 108.24% from the prior year.
  • Debt Ratio rose to 0.1 in Q1 2026 per RCUS's latest filing, from 0.09 in the prior quarter.
  • Across five years, Debt Ratio topped out at 0.1 in Q3 2025 and bottomed at 0.04 in Q3 2024.
  • The 3-year median for Debt Ratio is 0.09 (2025), against an average of 0.07.
  • Biggest YoY gain for Debt Ratio was 178.3% in 2025; the steepest drop was 108.24% in 2025.
  • Year by year, Debt Ratio stood at 0.04 in 2024, then surged by 108.24% to 0.09 in 2025, then rose by 15.4% to 0.1 in 2026.
  • Per Business Quant, the three latest RCUS Debt Ratio figures stand at 0.1 (Q1 2026), 0.09 (Q4 2025), and 0.1 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 1.41
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 0.11
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 0.05
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Arcus Biosciences 3.73 Bn 2.90 Bn - 0.10

Historic Data

Download Data
DateValue
Mar 31, 2026 0.10
Dec 31, 2025 0.09
Sep 30, 2025 0.10
Jun 30, 2025 0.09
Mar 31, 2025 0.04
Dec 31, 2024 0.04
Sep 30, 2024 0.04